VACCINEX INC
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
VCNX$1.41-61.4%Stored close · as of Dec 17, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows (Unaudited)
(in thousands)
| Three Months Ended March 31, | |||
|---|---|---|---|
| 2024 · 2023 | |||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||
| Net loss | $(3,897) | $(4,962) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation | 27 | 31 | |
| Stock-based compensation | 96 | 129 | |
| Change in fair value of warrant liability | (1,206) | - | |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (64) | 175 | |
| Prepaid expenses and other current assets | (459) | (183) | |
| Accounts payable | 290 | (425) | |
| Accrued expenses | 585 | 195 | |
| Deferred revenue | (4) | - | |
| Net cash used in operating activities | (4,632) | (5,040) | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||
| Purchase of property and equipment | - | (49) | |
| Net cash used in investing activities | - | (49) | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||
| Proceeds from issuance of common stock, andpre-funded warrants in private placement offerings | 2,529 | - | |
| Proceeds from issuance of warrants in private placement offerings | 1,113 | - | |
| Proceeds from private offering of common stock | - | 2,040 | |
| Payments of long-term debt | (19) | (19) | |
| Proceeds from issuance of common stock, andprivate placement warrants | 2,446 | - | |
| Net cash provided by financing activities | 6,069 | 2,021 | |
| NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS | 1,437 | (3,068) | |
| CASH AND CASH EQUIVALENTS–Beginning of period | 1,535 | 6,391 | |
| CASH AND CASH EQUIVALENTS–End of period | $2,972 | $3,323 | |
| SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES: | |||
| Issuance of preferred stock included in Accounts Receivable | $1,141 | $ | - |
| Issuance of private placement warrants included in Accounts Receivable | $556 | ||
| Issuance costs of preferred stock and private placement warrants included in Accrued expenses | $(53) | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.